Form 4: Arcutis Biotherapeutics CFO David Topper Receives Stock Options and Restricted Stock Units

David Topper, CFO of Arcutis Biotherapeutics, was granted stock options and restricted stock units on April 10, 2024, according to a Form 4 filing with the SEC.

Summary

• David Topper, the Chief Financial Officer of Arcutis Biotherapeutics, Inc., received 110,000 shares of common stock in the form of Restricted Stock Units (RSUs) on April 10, 2024.
• These RSUs will vest in four equal installments on each annual anniversary of April 10, 2024, contingent upon Topper's continued service.
• Topper also received options to purchase 310,000 shares of common stock at an exercise price of $12.34 per share on April 10, 2024.
• These options will vest as to 25% of the shares on the first annual anniversary of the grant date, with the remaining options vesting monthly at a rate of 2.0833% thereafter, also subject to continued service.
• Following these transactions, Topper directly owns 110,000 shares of common stock and options to purchase 310,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and suggests confidence in the company's future performance, but it's not a major event.

Positives

• The granting of RSUs and stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedules encourage long-term commitment from the CFO.

Industry Context

Granting stock options and RSUs to executives is a common practice in the biotechnology industry to attract and retain talent, and to align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also use stock options and RSUs to incentivize their executives.
• The vesting schedules described are typical for these types of grants.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively, as it aligns management's interests with theirs.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates